Svend Andersen Buys 7,200 Shares of Perrigo Company PLC (PRGO) Stock
Perrigo Company PLC (NYSE:PRGO) EVP Svend Andersen bought 7,200 shares of the company’s stock in a transaction on Tuesday, August 14th. The stock was purchased at an average price of $69.43 per share, with a total value of $499,896.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of PRGO stock opened at $72.96 on Friday. The company has a market capitalization of $9.56 billion, a price-to-earnings ratio of 14.80, a price-to-earnings-growth ratio of 1.74 and a beta of 0.84. The company has a quick ratio of 1.23, a current ratio of 1.81 and a debt-to-equity ratio of 0.52. Perrigo Company PLC has a fifty-two week low of $67.53 and a fifty-two week high of $95.93.
Perrigo (NYSE:PRGO) last issued its earnings results on Thursday, August 9th. The company reported $1.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.21 by $0.01. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.23 billion. Perrigo had a return on equity of 11.92% and a net margin of 4.77%. The firm’s revenue for the quarter was down 4.2% on a year-over-year basis. During the same period in the previous year, the company posted $1.22 earnings per share. research analysts anticipate that Perrigo Company PLC will post 4.95 earnings per share for the current year.
A number of equities analysts have recently issued reports on PRGO shares. Cantor Fitzgerald set a $107.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Tuesday, May 8th. Wells Fargo & Co lowered their price objective on Perrigo from $90.00 to $84.00 and set a “market perform” rating for the company in a research report on Monday, May 14th. Canaccord Genuity set a $105.00 price objective on Perrigo and gave the stock a “buy” rating in a research report on Monday, May 14th. Royal Bank of Canada lowered their price objective on Perrigo from $89.00 to $67.00 and set a “hold” rating for the company in a research report on Friday, August 10th. Finally, Deutsche Bank downgraded Perrigo from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $93.00 to $78.00 in a research report on Friday, August 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $89.06.
Hedge funds have recently modified their holdings of the business. Analyst IMS Investment Management Services Ltd. increased its holdings in Perrigo by 4.5% in the second quarter. Analyst IMS Investment Management Services Ltd. now owns 37,593 shares of the company’s stock worth $2,749,000 after purchasing an additional 1,635 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its holdings in Perrigo by 96.7% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 512,465 shares of the company’s stock worth $37,364,000 after purchasing an additional 251,953 shares in the last quarter. BlackRock Inc. increased its holdings in Perrigo by 1.0% in the first quarter. BlackRock Inc. now owns 8,682,619 shares of the company’s stock worth $723,608,000 after purchasing an additional 82,207 shares in the last quarter. Virginia Retirement Systems ET AL increased its holdings in Perrigo by 49.7% in the first quarter. Virginia Retirement Systems ET AL now owns 58,400 shares of the company’s stock worth $4,867,000 after purchasing an additional 19,400 shares in the last quarter. Finally, IBM Retirement Fund bought a new stake in Perrigo in the first quarter worth approximately $242,000. Institutional investors and hedge funds own 80.89% of the company’s stock.
Perrigo Company Profile
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Recommended Story: Investing in Growth Stocks
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.